Related Experiment Video
Updated: Dec 8, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.3K
Evolving targets for anti-epileptic drug discovery
Dezaree Raut1, Lokesh Kumar Bhatt1
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India.
European Journal of Pharmacology
|September 20, 2020
Summary
This review explores novel targets for anti-epileptic drug discovery to address pharmacoresistant epilepsy and adverse effects common with current treatments.
Area of Science:
- Neurology
- Pharmacology
- Drug Discovery
Background:
- Epilepsy affects 70 million globally, with current drugs offering symptomatic relief.
- Existing anti-epileptic drugs target neurotransmitter balance but 30% of patients remain pharmacoresistant.
- Adverse effects and comorbidities are significant challenges with current epilepsy treatments.
Purpose of the Study:
- To review experimental findings for novel anti-epileptic drug targets.
- To explore new signaling cascades for epilepsy treatment development.
- To identify potential therapeutic strategies beyond current pharmacotherapy.
Main Methods:
- Literature review of experimental findings in epilepsy research.
- Analysis of current anti-epileptic drug mechanisms and limitations.
- Identification of emerging targets and signaling pathways.
Main Results:
- Several experimental findings suggest potential novel drug targets.
- New signaling cascades offer alternative therapeutic avenues.
- Focus on novel targets could overcome pharmacoresistance.
Conclusions:
- Novel targets and signaling cascades are crucial for developing next-generation anti-epileptic drugs.
- Addressing pharmacoresistance requires exploring new therapeutic strategies.
- Further research into identified targets may lead to improved epilepsy management.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
995
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
995
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.0K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.0K
01:26Drug Discovery: Overview
10.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.6K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
672
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
672
01:20Antiepileptic Drugs: Potassium Channel Activators
490
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
490
01:26Targets for Drug Action: Overview
9.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.7K